Skip to content

Minocycline in the treatment of schizophrenia

Minocycline as adjuvant therapy on negative symptoms in patients with chronic schizophrenia that are receiving resperidon: a double blind and placebo controlled randomized clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201202241556N34
Enrollment
50
Registered
2012-03-01
Start date
2012-03-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. schizophrenia

Interventions

Intervention 1: Tablets Risperidone (6 mg/day) combined with 200mg/day Minocycline as intervention group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with placebo as control gro
Treatment - Drugs
Placebo
Tablets Risperidone (6 mg/day) combined with 200mg/day Minocycline as intervention group for 8 weeks

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 18-50; Diagnosis of Schizophrenia based on DSM IV; chronic Schizophrenia( duration of the disorder>2 years); Stable on antipsychotics Exclusion Criteria: Substance dependence; IQ <70; any other mental disorder on axis I; Any serious medical or neurological problem ; receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month; receiving ECT during the last 14 days; hepatic disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026